NPS Pharmaceuticals

Latest Headlines

Latest Headlines

Flush-with-cash Shire revisits deal for NPS Pharma

Armed with a $1.64 billion breakup fee from former merger partner AbbVie and a brand-new $2.1 billion revolving loan facility, Shire looks ready to strike a deal. Rumor says it's revisiting some of its old targets, including New Jersey's NPS Pharmaceuticals.

NPS Pharma will have to wait another three months for an FDA OK

The FDA has postponed its final decision on an orphan drug from NPS Pharma, taking its time with the company's application and delaying the fate of a closely watched therapy.

NPS slides as faint panel praise puts FDA approval in jeopardy

NPS Pharmaceuticals walked away from an FDA panel meeting with a recommendation to approve its orphan drug, but a lukewarm reception and nagging safety concerns have investors fearing the worst.

NPS jumps as FDA reviewers take little issue with orphan drug

NPS Pharma is moving toward FDA approval with its treatment for a rare disease, as agency staff applauded the drug's efficacy ahead of a make-or-break panel vote.

Analysts: Shire must go shopping to stay independent

Rumors that Shire is preparing a 10-figure bid for NPS Pharma may have been overblown, but analysts say the Irish drugmaker should take a hard look at M&A if it wants to avoid becoming a target in its own right.

NPS throws ice water on $4B Shire rumor, but Wall Street keeps the faith

The story about Shire making a $4 billion advance on NPS Pharmaceuticals? Never happened, according to the latter company, which broke long-standing industry tradition by publicly commenting on a market rumor.

Shire's $4B NPS buyout rumor grows legs with latest chatter

A questionable Friday rumor has evolved into a market-moving clamor, as London's Times reports that Shire has locked down a $5 billion credit facility and intends to make a bid for specialty drugmaker NPS Pharma.

Buzz: Shire eyes NPS for $4B amid an M&A blitz

Citing "usually well-informed sources," the Financial Times reports that Shire is considering a $4 billion bid for rare disease specialist NPS Pharma, a deal that would bolster the company's last blockbuster acquisition and perhaps get it out of rivals' crosshairs.

NPS, Iroko show how companies can grow sales, not staff

Big Pharma has been whacking a lot of jobs in the last couple of years, part of its periodic boom-and-bust cycle of hiring when times are good and firing when they are not. But some small drug companies have been trying a different model: Just don't add employees in the first place.

With NIH support, Eli Lilly follows NPS Pharma into hunt for rare-disease therapy

Eli Lilly has found a new path into the hot rare-disease field. An NIH program has backed the Indianapolis-based drug giant's preclinical-stage research of a potential treatment for a hormone deficiency often caused by a genetic defect.